pp 1-8 | Cite as

Epidemiology of Pulmonary Aspergillosis in Hospitalized Patients in Poland During 2009–2016

  • Patryk Tarka
  • Aneta Nitsch-Osuch
  • Paweł Gorynski
  • Piotr Tyszko
  • Magdalena Bogdan
  • Krzysztof KaneckiEmail author
Part of the Advances in Experimental Medicine and Biology book series


Aspergillus is one of the most prevalent airborne fungal pathogens in the developed countries that may cause fatal invasive pulmonary aspergillosis in immunocompromised patients. The epidemiological information on aspergillosis in Poland is scarce. This retrospective, population-based study evaluated the incidence of pulmonary and other forms of aspergillosis, and also gender distribution and territorial differences in the occurrence of aspergillosis in hospitalized patients in Poland during 2009–2016. The incidence of aspergillosis was estimated on the basis of a dataset provided by hospital morbidity study carried out by the National Institute of Public Health. The data consisted of 4206 hospitalization records of 2338 patients, with some patients being hospitalized more than one time due to disease remissions. Significant gender differences were observed (1484 females vs. 2722 males, p < 0.001). No statistical differences were found for the place of residence. The average annual incidence rates for all forms of aspergillosis, invasive pulmonary aspergillosis, and other pulmonary aspergillosis were 13.8 per million (95% CI: 11.3–16.3), 4 per million (95% CI: 3–5), and 4.4 (CI: 3.5–5.2) per million, respectively. Over time, a significant increase in the rate of hospitalization were observed for all forms of aspergillosis (10.7 per million in 2009 vs. 15.7 per million in 2016, p for trend <0.005), invasive pulmonary aspergillosis (2.3 per million in 2009 vs. 5 per million in 2016, p for trend <0.001), and other pulmonary aspergillosis (3.6 per million in 2009 vs. 4.9 per million in 2016, P for trend <0.02). During the period analyzed 283 patients (12%) died while hospitalized and 224 of them (9.6% of all patients) died during the first-time hospitalization. We conclude that the incidence of aspergillosis is on the rise in hospitalized patients in Poland.


Epidemiology Hospitalized patients Infection Morbidity Pulmonary aspergillosis 


Conflicts of Interest

Authors declare no conflicts of interest in relation to this article.

Ethical Approval

This article is a retrospective study based on the analysis of hospital discharge files. Therefore, the article does not contain any studies with human participants performed by any of the authors. A local Bioethics Committee of Warsaw Medical University in Poland has approved the study.


  1. Abramson JH (2011) WINPEPI updated: computer programs for epidemiologists, and their teaching potential. Epidemiol Perspec Innov 8(1):1. Scholar
  2. Agarwal R, Denning DW, Chakrabarti A (2014) Estimation of the burden of chronic and allergic pulmonary aspergillosis in India. PLoS One 9:e114745Google Scholar
  3. Al Shair K, Atherton GT, Harris C, Ratcliffe L, Newtop PJ, Denning DW (2013) Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis. Clin Infect Dis 57:828–835Google Scholar
  4. Baddley JW, Stephens JM, Ji X, Gao X, Schlamm HT, Tarallo M (2013) Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes. BMC Infect Dis 13:29. Scholar
  5. Blanchard E, Gabriel F, Jeanne-Leroyer C, Servant V, Dumas P-Y (2018) Invasive pulmonary aspergillosis. (Article in French). Rev Mal Respir 35:171–187Google Scholar
  6. Borys M, Piwowarczyk P, Sysiak J, Czuczwar M, Prystupa A (2017) Early diagnosis and treatment of invasive aspergillosis as a main determinant of outcome – review of literature according to the presented case report. Ann Agric Environ Med 24:100–103Google Scholar
  7. Cadranel J, Philippe B, Hennequin C, Bergeron A, Bergot E, Bourdin A, Cottin V, Jeanfaivre T, Godet C, Pineau M, Germaud P (2012) Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Eur J Clin Microbiol Infect Dis 31:3231–3239Google Scholar
  8. Central Statistical Office of Poland (2018) Accessed on 30 July 2018
  9. Chakrabarti A, Chatterjee SS, Das A, Shivaprakash MR (2011) Invasive aspergillosis in developing countries. Med Mycol 49(Suppl 1):35–47Google Scholar
  10. Chan JF, Lau SK, Wong SC, To KK, So SY, Leung SS, Chan SM, Pang CM, Xiao C, Hung IF, Cheng VC, Yuen KY, Woo PC (2016) A 10-year study reveals clinical and laboratory evidence for the “semi-invasive” properties of chronic pulmonary aspergillosis. Emerg Microbes Infect 5:e37Google Scholar
  11. Chrdle A, Mallátová N, Vašáková M, Haber J, Denning DW (2015) Burden of serious fungal infections in the Czech Republic. Mycoses 58(Suppl 5):6–14Google Scholar
  12. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813–1821Google Scholar
  13. Dell Inc (2016) Dell Statistica – data analysis software system, version 13. Accessed on 13 Dec 2018
  14. Denning DW, Cadranel J, Beigelman-Aubry C, Ader F, Chakrabarti A, Blot S, Ullmann AJ, Dimopoulos G, Lange C on behalf of the European Society for Clinical Microbiology and Infectious Diseases and European Respiratory Society (2016) Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J 47:45–68Google Scholar
  15. Gamaletsou MN, Drogari-Apiranthitou M, Denning DW, Sipsas NV (2016) An estimate of the burden of serious fungal diseases in Greece. Eur J Clin Microbiol Infect Dis 35:1115–1120Google Scholar
  16. Gangneux J-P, Bougnoux M-E, Hennequin C, Godet C, Chandenier J, Denning DW, Dupont B (2016) An estimation of burden of serious fungal infections in France. J Mycol Med 26:385–390Google Scholar
  17. Hou X, Zhang H, Kou L, Lv W, Lu J, Li J (2017) Clinical features and diagnosis of chronic pulmonary aspergillosis in Chinese patients. Medicine (Baltimore) 96:e8315Google Scholar
  18. Kim A, Nicolau DP, Kuti JL (2011) Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States. Mycoses 54:e301–e312Google Scholar
  19. Lagrou K, Maertens J, Van Even E, Denning DW (2015) Burden of serious fungal infections in Belgium. Mycoses 58(Suppl 5):1–5Google Scholar
  20. Lortholary O, Gangneux J-P, Sitbon K, Lebeau B, de Monbrison F, Le Strat Y, Coignard B, Dromer F, Bretagne S, for the French Mycosis Study Group (2011) Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007). Clin Microbiol Infect 17:1882–1889Google Scholar
  21. Lowes D, Al-Shair K, Newton PJ, Morris J, Harris C, Rautemaa-Richardson R, Denning DW (2017) Predictors of mortality in chronic pulmonary aspergillosis. Eur Respir J 49(2):pii: 1601062. Scholar
  22. Mareș M, Moroti-Constantinescu VR, Denning DW (2018) The burden of fungal diseases in Romania. J Fungi (Basel) 4(1):31. Scholar
  23. Mortensen KL, Denning DW, Arendrup MC (2015) The burden of fungal disease in Denmark. Mycoses 58(Suppl 5):15–21Google Scholar
  24. Nakamoto K, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y (2013) Prognostic factors in 194 patients with chronic necrotizing pulmonary aspergillosis. Intern Med 52:727–734Google Scholar
  25. Nordøy I, Hesstvedt L, Torp Andersen C, Mylvaganam H, Kols NI, Falch BM, Tofteland S, Müller F, Denning DW (2018) An estimate of the burden of fungal disease in Norway. J Fungi (Basel) 4(1):pii: E29. Scholar
  26. Ohba H, Miwa S, Shirai M, Kanai M, Eifuku T, Suda T, Hayakawa H, Chida K (2012) Clinical characteristics and prognosis of chronic pulmonary aspergillosis. Respir Med 106:724–729Google Scholar
  27. Pegorie M, Denning DW, Welfare W (2017) Estimating the burden of invasive and serious fungal disease in the United Kingdom. J Infect 74:60–71Google Scholar
  28. Remiszewski P, Langfort R, Podsiadło B, Kuś J, Płodziszewska M, Radzikowska E, Roszkowska B, Szopiński J, Tomkowski W, Wawrzyńska L, Wiatr E, Wierzbicka M, Załeska J, Załeska M, Zych J, Rowińska-Zakrzewska E (2002) Invasive aspergillosis in autopsy material of patients treated at the Institute of Tuberculosis and Chest Diseases during the years 1993–2000. Pneumonol Alergol Pol 70:251–257. (Article in Polish)Google Scholar
  29. Riera FO, Caeiro JP, Denning DW (2018) Burden of serious fungal infections in Argentina. J Fungi (Basel) 4(2):51. Scholar
  30. Rodriguez-Tudela JL, Alastruey-Izquierdo A, Gago S, Cuenca-Estrella M, León C, Miro JM, Nuñez Boluda A, Ruiz Camps I, Sole A, Denning DW, University of Manchester in association with the LIFE program (2015) Burden of serious fungal infections in Spain. Clin Microbiol Infect 21:183–189Google Scholar
  31. Ruhnke M, Groll AH, Mayser P, Ullmann AJ, Mendling W, Hof H, Denning DW, University of Manchester in association with the LIFE program (2015) Mycoses 58(Suppl 5):22–28Google Scholar
  32. Sabino R, Verissímo C, Brandão J, Martins C, Alves D, Pais C, Denning DW (2017) Serious fungal infections in Portugal. Eur J Clin Microbiol Infect Dis 36:1345–1352Google Scholar
  33. Steinbach WJ, Marr KA, Anaissie EJ, Azie N, Quan S-P, Meier-Kriesche H-U, Apewokin S, Horn DL (2012) Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect 65:453–464Google Scholar
  34. Sulik-Tyszka B, Kacprzyk P, Mądry K, Ziarkiewicz-Wróblewska B, Jędrzejczak W, Wróblewska M (2016) Aspergillosis of the heart and lung and review of published reports on fungal endocarditis. Mycopathologia 181:583–588Google Scholar
  35. Sun KS, Tsai CF, Chen SC, Chen YY, Huang WC (2016) Galactomannan testing and the incidence of invasive pulmonary aspergillosis: a 10-year nationwide population-based study in Taiwan. PLoS One 11:e0149964Google Scholar
  36. Swoboda-Kopeć E, Sikora M, Piskorska K, Gołaś M, Netsvyetayeva I, Przybyłowska D, Mierzwińska-Nastalska E (2017) Diagnosis of invasive pulmonary aspergillosis. Adv Exp Med Biol 944:27–33Google Scholar
  37. Taccone FS, Van den Abeele A-M, Bulpa P, Misset B, Meersseman W, Cardoso T, Paiva JA, Blanco-Navalpotro M, De Laere E, Dimopoulos G, Rello J, Vogelaers D, Blot SI, Study Investigators AICU (2015) Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Crit Care 19:7. Scholar
  38. Zieliński M, Mazur-Zielińska H, Ziora D (2016) Aspergilloma in atypical localisation in severe asthma patient – case report. Pneumonol Alergol Pol 84:181–185Google Scholar
  39. Zilberberg MD, Nathanson BH, Harrington R, Spalding JR, Shorr AF (2018) Epidemiology and outcomes of hospitalizations with invasive aspergillosis in the United States, 2009–2013. Clin Infect Dis 67(5):727–735Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Patryk Tarka
    • 1
  • Aneta Nitsch-Osuch
    • 1
  • Paweł Gorynski
    • 2
  • Piotr Tyszko
    • 3
  • Magdalena Bogdan
    • 1
  • Krzysztof Kanecki
    • 1
    Email author
  1. 1.Department of Social Medicine and Public HealthMedical University of WarsawWarsawPoland
  2. 2.National Institute of Public Health-National Institute of HygieneWarsawPoland
  3. 3.Institute of Rural Health in LublinLublinPoland

Personalised recommendations